Tapentadol in Chronic Malignant Tumour Related Pain

Pain Clinical Trial

Official title:

Open-label, Single-arm, Flexible Dosing, Phase III Trial, With Oral Tapentadol Prolonged Release (PR) in Subjects With Chronic Malignant Tumor-related Pain Who Have Completed the Maintenance Period of the KF5503/15 Trial.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01264887
• Other study ID #: KF5503/52
• Secondary ID: 2009-013291-4616
• Status: Terminated
• Phase: Phase 3
• Start date: March 2011
• Est. completion date: May 2014

Study information

• Verified date: October 2019
• Source: Grünenthal GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is the characterization of the long term safety profile and long-term dose requirements of tapentadol PR (prolonged release) in patients with malignant tumor-related pain. In the United States the prolonged-release formulation is also referred to as the extended-release formulation.

Description:

The prevalence of tumor-related pain is high and the treatment of chronic tumor-related pain remains a challenging therapeutic problem.

Participants directly entering the KF5503/52 trial from the KF5503/15 trial (i.e., within 7 days of Visit 8 of the KF5503/15 trial) is scheduled: a Transfer Visit, an Open-label Treatment Period and a Follow-up Period.

For participants with a gap of more than 7 days and less than 24 weeks, between their full completion of the KF5503/15 trial and entry into the KF5503/52 trial the following is scheduled: an Enrollment Visit, an Entry Visit for assessment of eligibility, an Open-label Treatment Period and a Follow-up Period.

This trial was designed to offer patients with chronic malignant tumor-related pain the option of continuing treatment by receiving tapentadol prolonged release (PR).

The protocol scheduled visits every 28 days during the open-label treatment period. Unscheduled visits (or at least unscheduled telephone calls) were planned when dose adjustment is required. If a visit is not possible at the time of dose change, it could be done up to 7 days later. Unscheduled visits could also be performed whenever considered necessary (i.e., for evaluation of adverse events).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 31
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants must have signed an Informed Consent Form.

• At least 18 years of age.

• Male and non-pregnant, non-lactating female subjects. Sexually active women must be post menopausal, surgically sterile, or practicing an effective method of birth control before entry and throughout the trial. Female participants of child-bearing potential must have a negative pregnancy test at enrollment.

• Within 24 weeks of either full completion or completion of the double-blind treatment period (Visit 8) of KF5503/15 trial performed in participants with moderate to severe chronic malignant tumor related pain.

• Participant is, in the opinion of the investigator, expected to continue to have an overall positive benefit/risk ratio from continuing analgesic treatment within this trial.

• Participant must be willing to take tapentadol prolonged release (PR) throughout their participation in the trial.

Exclusion Criteria:

• History of alcohol and/or drug abuse.

• The participant has a clinically significant disease other than cancer that in the Investigator's opinion may affect the safety of the participant.

• Employees of the investigator or trial center or family members of the employees or the investigator.

• Known to or suspected of not being able to comply with the protocol and the use of tapentadol prolonged release (PR).

• Concurrent participation in another trial (except for participation in the KF5503/15 trial) or planning to be enrolled in another clinical trial during the course of this trial.

• Previous participation in another trial between the end of KF5503/15 and enrollment into the current trial, KF5503/52.

• History of seizure disorder, epilepsy, traumatic brain injury, stroke or transient ischemic attack.

• Known history and/or presence of cerebral tumors or metastases.

• Rapidly escalating pain or pain uncontrolled by therapy and was previously treated with maximum dose level of Investigational Medicinal Product.

• Participant is taking any prohibited concomitant medications.

• Uncontrolled hypertension.

• Known moderate or severe hepatic impairment.

• Known severe renal impairment.

• Clinically relevant history of hypersensitivity, allergy, or contraindications to tapentadol or its excipients.

Related Conditions & MeSH terms

• Cancer
• Cancer Pain
• Chronic Pain
• Neoplasms
• Pain

Intervention

Drug:
• Tapentadol Prolonged Release
Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.

Locations

Country	Name	City	State
Bulgaria	Site 359004	Shumen
Hungary	Site 036002	Nyiregyhaza
Hungary	Site 036010	Szekszard
Moldova, Republic of	Site 373001	Chisinau
Poland	Site 048004	Bydgoszcz
Poland	Site 048001	Warszawa
Romania	Site 040006	Brasov
Romania	Site 040002	Bucharest
Russian Federation	Site 007007	Nizhniy Novgorod
Russian Federation	Site 007012	Vladikavkaz
Serbia	Site 381002	Nis
Serbia	Site 381001	Sremska Kamenica

Sponsors (1)

Lead Sponsor	Collaborator
Grünenthal GmbH

Countries where clinical trial is conducted

Bulgaria,  Hungary,  Moldova, Republic of,  Poland,  Romania,  Russian Federation,  Serbia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Average Pain Intensity (Over a Twelve-week Period)	The participant scored their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".; Average pain intensity score is the average of pain experienced for previous 24 hours as rated on an 11-point NRS at each visit. Calculations are based on 3 consecutive planned (at 4-weekly intervals) visits.; All available data of a participant was used; if a participant dropped-out or had incomplete data during a 12-week period no imputations were performed for the missing values.	Day 1; up to Week 144
Other	Average Daily Total Tapentadol Prolonged Release Dose	The Total Daily Dose (TDD) on any given day is the sum of the morning and evening intake amounts. The average TDD is an individuals average over the trial period.	Day 1; up to 144 weeks
Primary	Severity of Adverse Events	The severity of treatment emergent adverse events was any untoward medical occurrence in a patient administered tapentadol. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of the (investigational) medicinal product whether or not related to the use of tapentadol.; The clinical "intensity" of adverse event were classified as: Mild: signs and symptoms which can be easily tolerated. Symptoms could be ignored and disappeared when the participant is distracted.; Moderate: symptoms caused discomfort but were tolerable, they could not be ignored and affect concentration.; Severe: symptoms affected the usual daily activity.	Day 1; up to 144 weeks
Primary	Relatedness Assessment of Treatment Emergent Adverse Events	Participant-based analysis of treatment emergent adverse events (TEAEs) regarding the relationship to the study drug (tapentadol). The TEAEs were reported by the participants or were captured by the investigator. The relationship was rated by the investigator. The categorization of relatedness into one of the two categories was based on the following: Related included "possible", "probable/likely", and "certain"; whilst unrelated treatment emergent adverse events include those rated by the investigator as "unlikely", "conditional/unclassified", "un-assessable/unclassifiable", and "not related".	Day 1; up to 144 weeks
Primary	Countermeasures Taken Due to Treatment Emergent Adverse Events	Participant-based analysis of treatment emergent adverse events (TEAEs) regarding countermeasure to the study drug (tapentadol). The TEAEs were reported by the participants or were captured by the investigator. The countermeasure taken by the investigator were reported.	Day 1; up to 144 weeks
Primary	Time Dependence of Adverse Events	The onset and duration of TEAEs was not evaluated for this trial.	Day 1; 144 weeks
Secondary	Assess Consumption of Tapentadol During Long Term Use	Summary of the modal total daily dose during the treatment period. The modal dose was based on assessment of the consecutive morning and evening intake amounts on each day and evaluation of the total daily dose.	Day 1; up to 144 weeks
Secondary	Tapentadol Prolonged Release Exposure	The number of days that participants took tapentadol prolonged release. The extent of exposure was categorized into 2 periods, less than 90 days and more than 90 days (up to 144 weeks).	Day 1; up to 144 weeks